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Objective. Our aims were to evaluate the correlation between Juvenile Arthritis Disease Activity Score 27-joint reduced
count (JADAS27) with erythrocyte sedimentation rate (ESR) and JADAS27 with C-reactive protein (CRP) scores and to test
the agreement of both scores on classifying each disease activity state. We also aimed at verifying the correlation of the
2 scores across juvenile idiopathic arthritis (JIA) categories and to check the correlation between JADAS27-ESR and
clinical JADAS27 (JADAS27 without ESR).
Methods. A nationwide cohort of patients with JIA registered in the Portuguese Register, Reuma.pt, was studied.
JADAS27-CRP was adapted by replacing ESR with CRP level as the inﬂammatory marker. JADAS27-CRP was calculated
similarly to JADAS27-ESR as the simple linear sum of its 4 components. Pearson’s correlations and K statistics were used
in the analyses.
Results. A total of 358 children had full data to calculate JADAS27; 65.4% were female and the mean  SD disease
duration was 11.8  9.1 years. The correlation coefﬁcient between JADAS27-ESR and JADAS27-CRP was 0.967 (P <
0.0001), although the correlation coefﬁcient between ESR and CRP level was 0.335 (P < 0.0001). The strong correlation
between JADAS27-ESR and JADAS27-CRP was maintained when compared within each JIA category. The agreement
between JADAS27-ESR and JADAS27-CRP across the 4 activity states was very good, showing 91.1% of the observations
in agreement; K 0.867 (95% conﬁdence interval 0.824–0.91). The correlation between JADAS27 with ESR and JADAS27
without ESR was high (r  0.97, P < 0.0001).
Conclusion. JADAS27 based on CRP level correlated closely with JADAS27-ESR across all disease activity states and JIA
categories, indicating that both measures can be used in clinical practice. Moreover, the correlation of JADAS27 with and
without ESR was also high, suggesting that this tool might be useful even in the absence of laboratorial measures.
INTRODUCTION
Juvenile idiopathic arthritis (JIA) is the most common ar-
thritis of childhood. It is a heterogeneous disease group of
unknown etiology with distinct presentation, clinical fea-
tures, immunopathogenesis, and genetic background (1).
In fact, some of the categories of JIA may represent differ-
ent diseases. Evaluation of disease activity is a crucial
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component of the clinical assessment of children with JIA
because persistently active disease plays a major role in
causing joint damage and physical disability (2).
Recently, a composite score named Juvenile Arthritis
Disease Activity Score (JADAS) was found to be a valid
instrument for assessment of disease activity (2). JADAS
consists of 4 components: physician global assessment of
disease activity, parent/patient global assessment of well-
being, number of joints with active disease, and an inﬂam-
matory marker (2). The clinical measures included in
JADAS are part of the American College of Rheumatology
(ACR) pediatric core set of outcome variables (3). A major
advantage of JADAS when compared to ACR pediatric
measures of improvement criteria is the ability to assess
disease activity at a single visit and also to compare dis-
ease activity between individuals or groups. There are no
perfect instruments and the major caveat of JADAS is that
systemic features are not contemplated, limiting its use
in systemic JIA. According to the authors who validated
JADAS (2), the statistical performance of the JADAS 27-
joint reduced count (JADAS27) was comparable with that
provided by the JADAS71. However, assessment of 27
joints is more feasible and less tedious than evaluation of
71 joints. The simplest, 10-joint reduced count revealed
the best discriminating validity, responsiveness (although
not in nonresponder patients), and distribution, but had a
somewhat poorer construct validity. The greater respon-
siveness of this joint count may be explained by most JIA
patients having few joints involved. Use of this reduced
count, which does not enable a precise assessment of joint
disease and may limit the ability to detect new joint in-
volvement over time, is advised only for use in retrospec-
tive studies, when the total number of involved joints is
known, but no information on the individual affected joint
is available (2).
JADAS was developed using the erythrocyte sedimenta-
tion rate (ESR) because C-reactive protein (CRP) values
were not available in all databases used to validate the tool
(2). However, as the authors of the JADAS highlighted,
CRP level is a direct measure of the acute-phase response
and is less confounded by other factors when compared to
ESR. In rheumatoid arthritis (RA) the performance of the
Disease Activity Index of 28 joints (DAS28) based on CRP
level has been shown to have a similar proﬁle to DAS28
based on ESR (4,5). Similarly, Nordal et al recently com-
pared in a Nordic population the JADAS based on CRP
level with the JADAS based on ESR and concluded that
these instruments correlated closely, indicating that both
scores can be recommended for assessing disease activity
in JIA (6). Recently, cutoff values for classifying distinct
disease activity states were proposed for the JADAS-ESR
(7).
The aim of our work was to evaluate the correlation
between the JADAS27-ESR and the JADAS27-CRP and to
test the agreement of both scores for classifying each
disease activity state. We also aimed at verifying the
correlation of the 2 scores across all JIA categories and to
check the correlation between the JADAS27-ESR and the
JADAS27 without ESR.
PATIENTS AND METHODS
Population and ethical considerations. A nationwide
cohort of patients with JIA according to International
League of Associations for Rheumatology (ILAR) criteria,
registered in the Rheumatic Diseases Portuguese Register,
Reuma.pt (8), was studied. Patients with a diagnosis of JIA
were consecutively included in the study during the visit
in which they completed all study protocol and all disease
activity measures were available for JADAS27-ESR and
JADAS27-CRP calculation. Clinical information, inﬂam-
mation markers, and physician and parent/patient visual
analog scales (VAS) on global health were collected ac-
cording to the study protocol and inserted by physicians.
Questionnaires on self-reported physical disability were
also assessed, i.e., the Childhood Health Assessment Ques-
tionnaire (C-HAQ; where 0  best and 3  worst) for
children age 18 years (9), and the Health Assessment
Questionnaire (HAQ; where 0  best and 3  worst) (10)
for participants age 18 years. JIA categories were classi-
ﬁed according to the ILAR criteria (11).
Parents and children between ages 12 and 18 years gave
informed consent, as well as patients age 18 years. Re-
uma.pt was approved by the National Board of Data Pro-
tection and local ethics committees. Research was carried
out in compliance with the Declaration of Helsinki, and all
the ethics committees of the participating hospitals and
clinics approved the study.
JADAS calculation. JADAS consists of 4 components:
physician global assessment of disease activity on a 10-cm
VAS (where 0  no activity and 10  maximum activity),
parent/patient global assessment of well-being on a 10-cm
VAS (where 0  very well and 10  very poor), number of
joints with active disease, and an inﬂammatory marker
PhD: Hospital Egas Moniz, Centro Hospitalar Lisboa Oci-
dental and CEDOC, New Faculty of Medical Sciences, Lis-
bon, Portugal; 15Joa˜o E. Fonseca, MD, PhD, Helena Canha˜o,
MD, PhD: Instituto de Medicina Molecular and Lisbon Ac-
ademic Medical Center, Lisbon, Portugal.
Address correspondence to Ana F. Moura˜o, MD, Rheuma-
tology Research Unit, Instituto de Medicina Molecular,
Avenida Professor Egas Moniz, Edifı´cio Egas Moniz, 1649-
028 Lisbon, Portugal. E-mail: aﬁlipamourao@gmail.com.
Submitted for publication May 10, 2013; accepted in re-
vised form October 15, 2013.
Signiﬁcance & Innovations
● Juvenile Arthritis Disease Activity Score (JADAS)
is a valid instrument for assessment of disease
activity in juvenile idiopathic arthritis.
● JADAS based on erythrocyte sedimentation rate
(ESR) correlated closely with JADAS based on C-
reactive protein level.
● The correlation of JADAS with and without ESR is
also high, suggesting that this tool might be useful
even in the absence of laboratory measures.
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(ESR) (2). We decided to use the 27-joint reduced count
(JADAS27) due to its greater feasibility. This count has
been found to be a valid surrogate for the whole joint count
in JIA (12). The JADAS27 includes the following joints:
cervical spine, elbows, wrists, metacarpophalangeal joints
(from the ﬁrst to third), proximal interphalangeal joints,
hips, knees, and ankles. The ESR value was normalized to
a 0–10 scale according to the following formula:
ESR mm/hour 20
10
Before making the calculation, ESR values 20 mm/
hour were converted to 0 and ESR values 120 were
converted to 10 (2).
Similarly to Nordal et al, JADAS27-CRP was adapted by
replacing ESR with CRP level as the inﬂammatory marker




This is similar to the truncated ESR used in JADAS (2).
Before calculation, CRP values 10 mg/liter were con-
verted to 0 and CRP values 110 mg/liter were converted
to 10. JADAS27-CRP was calculated similarly to JADAS27-
ESR, as the simple linear sum of its 4 components,
yielding a global score of 0–57, which is also similar to
JADAS27-ESR.
Cutoff values for inactive disease, minimal disease ac-
tivity, acceptable symptom state, and active disease. Re-
cently, Consolaro et al (7) deﬁned, for all versions of
JADAS-ESR (JADAS10, JADAS27, and JADAS71), the cut-
off score for classifying a patient as having “inactive dis-
ease” as 1 for all JIA categories. The cutoff for classiﬁ-
cation of “minimal disease activity” was 1 and 2 for
oligoarticular JIA and 1 and 3.8 for polyarticular JIA.
Children with systemic arthritis, rheumatoid factor (RF)–
positive polyarthritis, RF-negative polyarthritis, or ex-
tended oligoarthritis were included in the polyarthritis
group. The oligoarthritis group included patients with per-
sistent oligoarthritis. Patients with JIA classiﬁed in the
remaining ILAR categories were assigned to the polyarthri-
tis or oligoarthritis group based on the number of joints
affected during disease course (4 or 4, respectively).
Cutoff values for JADAS for “parent’s acceptable symptom
state” was2 and3.2 for oligoarticular JIA and3.8 and
5.2 for polyarticular JIA (7). Values above the cutoffs for
“parent’s acceptable symptom state” were considered as
“active disease” state (JADAS 3.2 and JADAS 5.2 for
oligoarticular and polyarticular JIA, respectively).
We analyzed the agreement of the classiﬁcation of pa-
tients with the cutoffs of JADAS27 (using ESR) with the
JADAS27-CRP classiﬁcation using the categories of “inac-
tive disease,” “minimal disease activity,” “parent’s accept-
able symptom state,” and “active disease” to verify
whether these 2 JADAS versions were classifying the pa-
tients similarly.
Statistical analysis. Descriptive statistics were used to
summarize population characteristics. Correlations be-
tween the continuous variables were calculated and ex-
pressed as Pearson’s coefﬁcient correlation. Correlations
were considered high, moderate, or weak at coefﬁcients
0.7, 0.4–0.7, or 0.4, respectively. The Student’s t-test
and analysis of variance (ANOVA) were used to compare
means between groups. ANOVA followed by Bonferroni
analysis was used to compare the JADAS27-ESR and
JADAS27-CRP across all JIA categories. Pearson’s correla-
tions and K statistics were used to assess the agreement
between disease states set by JADAS27-ESR and JADAS27-
CRP. Statistical analysis was performed using SPSS statis-
tical software, version 20. Two-sided P values less than
0.05 were considered statistically signiﬁcant.
RESULTS
From the 729 patients with JIA included in the Reuma.pt
database, 358 children had full data to calculate JADAS27-
ESR and JADAS27-CRP. Of these 358 patients, 65.4% were
female. Mean  SD disease duration was 11.8  9.1 years
and the mean  SD age at the last visit was 18.5  9.9
years. A total of 134 patients (37.5%) were classiﬁed as
persistent oligoarticular, 53 patients (14.8%) as extended
oligoarticular, 51 patients (14.2%) were polyarticular RF
negative, 30 patients (8.4%) were polyarticular RF posi-
tive, 39 patients (10.9%) were systemic, 35 patients (9.8%)
had enthesitis-related arthritis, 11 patients (3.1%) had pso-
riatic arthritis, and in 5 patients (1.4%) information was
lacking on the category of JIA. The age, sex, disease dura-
tion, and JIA categories distribution of the selected pa-
tients (358 patients) was similar to the patients that were
excluded due to insufﬁcient data (371 patients).
The correlation coefﬁcient at the last visit with all
JADAS items available between JADAS27-ESR and
JADAS27-CRP was 0.967 (P  0.0001) (Figure 1), although
the correlation coefﬁcient between ESR and CRP level was
0.335 (P 0.0001) (this correlation refers to the raw values
of ESR and CRP level, not the truncated values used to
calculate JADAS27). When comparing the JADAS27-ESR
and JADAS27-CRP within each category of JIA, the strong
Figure 1. Correlation between Juvenile Arthritis Disease Activity
Score 27-joint reduced count (JADAS27) based on erythrocyte
sedimentation rate (ESR) and corresponding JADAS27 based on
C-reactive protein (CRP) level in the Portuguese Reuma.pt cohort,
at the same study visit (r  0.967, P  0.0001).
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correlation was maintained (all correlation coefﬁcients
0.8 and P values  0.001) (Table 1).
JADAS27-ESR and JADAS27-CRP according to JIA cate-
gories are shown in Table 1. The mean JADAS27-CRP of
the oligoarticular categories differed signiﬁcantly from the
mean JADAS27-CRP score of the polyarticular categories
(persistent oligoarticular versus polyarticular RF positive
[P  0.0001], persistent oligoarticular versus polyarticular
RF negative [P  0.010], and extended oligoarticular ver-
sus polyarticular RF positive [P  0.03]). The JADAS27-
ESR also differed signiﬁcantly between the oligoarticular
and polyarticular categories of JIA (persistent oligoarticu-
lar versus polyarticular RF positive [P  0.003] and per-
sistent oligoarticular versus polyarticular RF negative [P
0.01]).
From the 358 patients included in this study using the
JADAS27-ESR, 160 (44.7%) patients were classiﬁed as
having inactive disease, 42 (11.7%) had minimal disease
activity, 45 (12.6%) had acceptable symptom state, and
111 (31%) patients had active disease. The classiﬁca-
tion was similar using the JADAS27-CRP: 166 (46.4%)
patients were classiﬁed as having inactive disease, 41
(11.4%) had minimal disease activity, 39 (10.9%) had
acceptable symptom state, and 112 (31.3%) patients
Figure 2. Disease activity state according to Juvenile Arthritis Disease Activity Score (JADAS) based on eryth-
rocyte sedimentation rate (ESR) and JADAS based on C-reactive protein (CRP) level for the different juvenile
idiopathic arthritis (JIA) categories at the study visit, in the Portuguese Reuma.pt JIA cohort. PsorA  psoriatic
arthritis; ERA enthesitis-related arthritis; OligoE oligoarticular extended; OligoP oligoarticular persistent;
PolyRFneg  polyarticular rheumatoid factor negative; PolyRFpos  polyarticular rheumatoid factor positive;
SoJIA  systemic-onset JIA.








PsA 5.218  4.61 4.855  4.68 0.883 0.0003
ERA 3.731  4.29 3.514  3.87 0.973  0.0001
OligoE 3.128  4.11 3.002  3.93 0.976  0.0001
OligoP 2.569  4.05 2.309  3.66 0.970  0.0001
PolyRFneg 5.304  6.88 4.878  6.54 0.964  0.0001
PolyRFpos 6.217  5.42 6.263  5.46 0.964  0.0001
SoJIA 3.523  3.68 3.464  3.63 0.967  0.0001
All categories 3.661  4.82 3.447  4.58 0.967  0.0001
* JADAS27  Juvenile Arthritis Disease Activity Score 27-joint reduced count; ESR  erythrocyte
sedimentation rate; CRP C-reactive protein; JIA juvenile idiopathic arthritis; PsA psoriatic arthritis;
ERA  enthesitis-related arthritis; OligoE  oligoarticular extended; OligoP  oligoarticular persistent;
PolyRFneg  polyarticular rheumatoid factor negative; PolyRFpos  polyarticular rheumatoid factor
positive; SoJIA  systemic-onset JIA.
† Correlations were considered high when r  0.7, moderate if 0.4  r  0.7, and low if r  0.4.
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had active disease. Figure 2 shows the disease activity
states according to the different JIA categories based on
JADAS27-ESR and JADAS27-CRP. The agreement between
JADAS27-ESR and JADAS27-CRP across the 4 activity
states assessed by K statistics was very good, showing
91.1% of the observations in agreement: K  0.867 (95%
conﬁdence interval 0.824–0.91).
The correlation between JADAS27 with ESR and
JADAS27 without ESR (clinical JADAS27) was high (r 
0.97, P  0.0001), as well as the correlation between
JADAS27-CRP and JADAS27 without CRP (r  0.97, P 
0.0001). We analyzed separately the patients with higher
values of ESR (20 mm/hour, n  109) and increased
CRP level (10 mg/liter, n  70), and veriﬁed that the
correlation between JADAS27-ESR and clinical JADAS27
was still high (r  0.96, P  0.0001), as well as between
JADAS27-CRP and clinical JADAS27 (r  0.93, P 
0.0001). We also assessed whether the correlation between
clinical JADAS27 and the JADAS27 that included an in-
ﬂammatory marker still remained high in the systemic
subtype. The coefﬁcient correlation with clinical JADAS27
was 0.96 and 0.94, respectively, for JADAS27-ESR and
JADAS27-CRP. Table 2 shows the correlation between
JADAS-ESR and JADAS-CRP across all JIA disease activity
states.
Correlation between JADAS27-ESR and parent/patient
global assessment of well-being was strong (r  0.84, P 
0.0001) as well as the correlation between JADAS27-ESR
and physician global assessment of disease activity (r 
0.88, P  0.0001). We also tested the correlation between
physician global assessment of disease activity (VAS) and
parent/patient global assessment of well-being on a 10-cm
VAS; the correlation coefﬁcient was 0.64 (P  0.0001).
A moderate correlation (r  0.49) was found between
JADAS27-ESR and C-HAQ/HAQ (P  0.0001).
DISCUSSION
Composite indices or pooled indices are useful tools for
the evaluation of disease activity in patients with JIA.
They allow the integration of various aspects of the disease
into a single numerical value and may improve patient
care. The JADAS is a new tool for the evaluation of disease
activity in JIA that has been developed to provide physi-
cians with a simple and useful instrument.
Similar to the work of Nordal et al (6), in our study
the JADAS27 based on ESR and on CRP level correlated
closely, indicating that both measures can be used. In
addition, we have tested the recently published cutoff
Table 2. JADAS27-ESR and JADAS-CRP across JIA disease activity states and descriptive statistics of the components of
JADAS27 (number of joints with active disease, parent/patient global assessment of well-being, physician global assessment of











Patients, no. (%) 358 (100) 160 (44.69) 42 (11.73) 45 (12.57) 111 (31.01)
JADAS27-ESR
Mean  SD 3.71  4.86 0.18  0.31 1.78  0.66 3.36  0.97 9.67  4.52
Median (minimum, maximum) 1.5 (0, 30.6) 0 (0, 1.1) 1.55 (1.1, 3.8) 3.3 (2, 5.4) 9 (3.6, 30.6)
JADAS-CRP
Mean  SD 3.50  4.64 0.19  0.42 1.76  1.72 3.32  1.56 9.01  4.45
Median (minimum, maximum) 1.35 (0, 33) 0 (0, 3.1) 1.5 (0, 10) 3 (1.2, 8.4) 8.5 (1.2, 33)
JADAS-ESR vs. JADAS-CRP
r 0.967 0.697 0.496 0.593 0.925
P  0.0001  0.0001 0.0008  0.0001  0.0001
ESR, mm/hour
Mean  SD 17.12  17.16 9.74  6.83 16.36  12.7 19.49  16.8 27.09  23.11
Median (minimum, maximum) 12 (1, 120) 8 (1, 29) 14 (1, 44) 14 (1, 71) 20 (1, 120)
20, % 74.02 91.88 66.67 68.89 53.15
CRP, mg/liter
Mean  SD 7.01  14.24 3.04  4.88 5.89  11.43 10.78  17.0 11.63  20.2
Median (minimum, maximum) 2 (0, 156) 1 (0, 31.3) 2 (0, 51.9) 4 (0, 73.9) 4 (0, 156)
10, % 81.84 91.88 92.86 73.33 66.67
Active joints
Mean  SD 0.39  1.03 0  0 0.12  0.4 0.22  0.56 1.13  1.57
Median (minimum, maximum) 0 (0, 7) 0 (0, 0) 0 (0, 2) 0 (0, 3) 1 (0, 7)
PGA
Mean  SD 1.63  2.32 0.10  0.24 0.66  0.61 1.53  1.29 4.25  2.42
Median (minimum, maximum) 0.4 (0, 10) 0 (0, 1) 0.7 (0, 2) 1.2 (0, 5.2) 4 (0, 10)
PhGA
Mean  SD 1.15  1.7 0.04  0.16 0.59  0.56 0.97  0.74 3.05  1.86
Median (minimum, maximum) 0 (0, 9.3) 0 (0, 1.1) 0.5 (0, 2) 1 (0, 2.5) 2.9 (0, 9.3)
* JADAS27  Juvenile Arthritis Disease Activity Score 27-joint reduced count; ESR  erythrocyte sedimentation rate; CRP  C-reactive protein; JIA 
juvenile idiopathic arthritis; PGA  parent/patient global assessment of well-being (on a 10-cm visual analog scale [VAS], where 0  very well and
10  very poor); PhGA  physician global assessment of disease activity (on a 10-cm VAS, where 0  no activity and 10  maximum activity).
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criteria for classiﬁcation of inactive disease, minimal dis-
ease activity, parent’s acceptable symptom state (7), and
active disease to analyze whether patients were classiﬁed
in the same state using either JADAS27-ESR or CRP. The
criteria (i.e., cutoff values) were developed due to the need
for identifying different states of JIA activity and may
provide simple and intuitive reference values that can be
used to monitor the disease course over time in an indi-
vidual patient or to compare disease status across individ-
ual patients or patient groups (7). The agreement between
JADAS27-ESR and JADAS27-CRP across the 4 activity
states was very good, showing agreement in 91.1% of the
observations, reinforcing that clinicians can use both mea-
sures to calculate the JADAS without changing the catego-
ries in which the patients are classiﬁed.
JADAS calculation may have had some limitations in
our study population. Most of our JIA patients had inactive
disease, which might have enhanced the results. However,
when we performed the correlation of JADAS-ESR with
JADAS-CRP according to the disease activity states (Table
2), the patients with active disease showed a high correla-
tion (r  0.925, P  0.0001). Additionally, in patients with
values of ESR20 or CRP level10 (i.e., converted values
different than zero), the high correlation between the 2
scores was maintained (r  0.94, P  0.0001) (data not
shown).
Another limitation of JADAS is that the conversion of
the higher values of ESR and CRP level to 10 can mislead
the results: a JIA patient with CRP level of 200 mg/liter
obtains the same JADAS score as a patient with a CRP level
of 110 mg/liter (both values of CRP are converted to 10).
Finally, as the authors of JADAS point out, although the
score was designed to be robust enough to cover all cate-
gories of JIA, a thorough assessment of disease activity in
children with systemic JIA requires quantiﬁcation of ex-
traarticular manifestations, particularly fever and rash (2).
Measurement of CRP level presents some advantages
compared to ESR: CRP level is a direct measure of the
acute-phase response and is less confounded by other
factors, including comorbidities. Also, CRP level assess-
ment is more rapid and the cost is comparable to ESR (4).
Still, although the inclusion of CRP level and ESR is fully
justiﬁed by their face and content validity, the delay asso-
ciated with their assessment might be one reason why
many physicians do not apply composite scores to guide
their clinical decisions. In a study of RA, Aletaha et al
concluded that acute-phase reactants add little to compos-
ite disease activity indices (13). These inﬂammatory pa-
rameters did not seem to contribute with sufﬁciently im-
portant information to composite scores to change
judgment of disease activity, in addition to merely using
clinical measures. Because laboratory tests are frequently
missing at patient visits, we have also tested JADAS27
with and without ESR. The correlation between JADAS27
with ESR and JADAS27 without ESR (clinical JADAS) was
high (r  0.97, P  0.0001), indicating that when ESR is
not available JADAS27 can be calculated without this vari-
able. The clinical JADAS27 can therefore be used to con-
duct a disease activity evaluation anytime and anywhere.
Recently, McErlane et al concluded that for the majority of
JIA categories, clinical applicability of JADAS would be
improved by exclusion of ESR and that the amended score
(JADAS3-71), which omits the ESR, correlates well with
JADAS71 (14).
We have also tested the correlation between physician
global assessment of disease activity (VAS) and parent/
patient global assessment of well-being on a 10-cm VAS in
order to see whether it would be possible to cut one of
these components of JADAS27, similar to the DAS28 of 4
and 3 variables in RA (15). The correlation was moderate
and insufﬁcient to exclude a component from the tool.
In fact, it is crucial to include these 2 scales in JADAS.
Parent/patient global assessment is important because it is
the only parameter that incorporates the parent’s/patient’s
perception of disease activity. The physician global assess-
ment is also relevant because it represents the most re-
sponsive measure in JIA (2).
As with Consolaro et al (2), in our study the correla-
tion between JADAS27-ESR and functional impairment
according to C-HAQ/HAQ was only moderate (r  0.499,
P  0.0001). This moderate correlation was expected be-
cause C-HAQ/HAQ scores combine the effect of both dis-
ease activity and damage. The authors of JADAS decided
not to include functional status assessment because it
has been shown to be relatively insensitive to change in
JIA (2).
In conclusion, in our study the JADAS27 based on CRP
level and ESR correlated closely, and both classify patients
similarly regarding disease activity state, indicating that
both measures can be used interchangeably in clinical
practice. In addition, clinical JADAS, a score that does not
include laboratory measures, was also well correlated with
JADAS-ESR and JADAS-CRP.
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